248 related articles for article (PubMed ID: 31520152)
1. Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers.
Soma O; Hatakeyama S; Okamoto T; Fujita N; Hamano I; Tanaka T; Momota M; Yoneyama T; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Saitoh H; Nakaji S; Suzuki T; Ohyama C
Med Oncol; 2019 Sep; 36(10):88. PubMed ID: 31520152
[TBL] [Abstract][Full Text] [Related]
2. Clinical implication of a quantitative frailty assessment tool for prognosis in patients with urological cancers.
Soma O; Hatakeyama S; Okamoto T; Fujita N; Matsumoto T; Tobisawa Y; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Koie T; Nakaji S; Ohyama C
Oncotarget; 2018 Apr; 9(25):17396-17405. PubMed ID: 29707115
[TBL] [Abstract][Full Text] [Related]
3. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
4. Surgical palliation of incurable urologic cancer.
Alagiri M; Greenberg RE
Curr Probl Cancer; 1995; 19(6):360-71. PubMed ID: 8903673
[No Abstract] [Full Text] [Related]
5. Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
Ishii N; Hatakeyama S; Miura H; Tanaka R; Oishi T; Horiguchi H; Hosogoe S; Fujita N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Int J Urol; 2023 Jul; 30(7):572-578. PubMed ID: 36941076
[TBL] [Abstract][Full Text] [Related]
6. Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological Cancers.
Togashi K; Hatakeyama S; Soma O; Okita K; Fujita N; Tanaka T; Noro D; Horiguchi H; Uemura N; Iwane T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551713
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate kinase type tumor M2 in urological malignancies.
Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
[TBL] [Abstract][Full Text] [Related]
8. Grading and prognostic significance of urologic carcinomas.
Helpap B
Urol Int; 1992; 48(3):245-57. PubMed ID: 1589911
[TBL] [Abstract][Full Text] [Related]
9. The E-cadherin cell-cell adhesion pathway in urologic malignancies.
Morton RA; Ewing CM; Watkins JJ; Isaacs WB
World J Urol; 1995; 13(6):364-8. PubMed ID: 9116756
[TBL] [Abstract][Full Text] [Related]
10. Urologic cancer in China.
Pang C; Guan Y; Li H; Chen W; Zhu G
Jpn J Clin Oncol; 2016 Jun; 46(6):497-501. PubMed ID: 27049022
[TBL] [Abstract][Full Text] [Related]
11. Quantitative light microscopy in urological oncology.
van der Poel HG; Schaafsma HE; Vooijs GP; Debruyne FM; Schalken JA
J Urol; 1992 Jul; 148(1):1-13. PubMed ID: 1613843
[No Abstract] [Full Text] [Related]
12. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
Alevizopoulos A; Tyritzis S; Leotsakos I; Anastasopoulou I; Pournaras C; Kotsis P; Katsarou O; Alamanis C; Stravodimos K; Constantinides C
Int J Urol; 2017 Feb; 24(2):130-136. PubMed ID: 28004432
[TBL] [Abstract][Full Text] [Related]
13. Role of Geriatric Oncologists in Optimizing Care of Urological Oncology Patients.
Droz JP; Boyle H; Albrand G; Mottet N; Puts M
Eur Urol Focus; 2017 Oct; 3(4-5):385-394. PubMed ID: 29128297
[TBL] [Abstract][Full Text] [Related]
14. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
Aveta A; Cilio S; Contieri R; Spena G; Napolitano L; Manfredi C; Franco A; Crocerossa F; Cerrato C; Ferro M; Del Giudice F; Verze P; Lasorsa F; Salonia A; Nair R; Walz J; Lucarelli G; Pandolfo SD
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446024
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions.
Monfardini S; Morlino S; Valdagni R; Catanzaro M; Tafa A; Bortolato B; Petralia G; Bonetto E; Villa E; Picozzi S; Locatelli MC; Galetti G; Millul A; Albanese Y; Bianchi E; Panzarino C; Gerardi F; Beghi E
J Geriatr Oncol; 2017 Jul; 8(4):289-295. PubMed ID: 28292646
[TBL] [Abstract][Full Text] [Related]
16. Frailty and functional decline indices predict poor outcomes in hospitalised older people.
Dent E; Chapman I; Howell S; Piantadosi C; Visvanathan R
Age Ageing; 2014 Jul; 43(4):477-84. PubMed ID: 24257468
[TBL] [Abstract][Full Text] [Related]
17. [Update uro-oncology: scientific meetings 2011].
Hegele A; Skrobek L; Schrader AJ
Aktuelle Urol; 2012 Jan; 43(1):13-27. PubMed ID: 22344822
[TBL] [Abstract][Full Text] [Related]
18. Gout patients have an increased risk of developing most cancers, especially urological cancers.
Chen CJ; Yen JH; Chang SJ
Scand J Rheumatol; 2014; 43(5):385-90. PubMed ID: 24825466
[TBL] [Abstract][Full Text] [Related]
19. Current status of chemotherapy sensitivity testing for urological malignancies.
Chin JL; Slocum HK; Bulbul MA; Rustum YM
J Urol; 1986 Sep; 136(3):555-60. PubMed ID: 3525862
[No Abstract] [Full Text] [Related]
20. [Sarcomatoid carcinoma of the urinary tract: clinical analysis of 16 cases].
Zhou C; Xie LP; Zheng XY
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):634-5. PubMed ID: 22325229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
